Answer
Nausea was reported in 7% of patients taking atogepant (Aquipta) in placebo-controlled migraine prevention studies and led to discontinuation in 0.6%.
Sources for this answer
- AQUIPTA 10 mg tabletsAbbVie Ltd · emc · SmPC §4.8 Undesirable effects · Version 4Document updated
Sources checked